臺灣博碩士論文加值系統

過去研究顯示葛根內一種異黃酮類的大豆苷原(Daidzein)可有效抑制大腸癌、子宮頸癌、胰臟癌以及乳癌的生長。而人類上皮生長因子接受體第2蛋白 (Human Epidermal Growth Factor Receptor 2 protein, p185HER2/neu ) 在許多癌症中發現有過度表現的現象。本研究發現Daidzein 在p185HER2/neu 過度表現的卵巢癌SKOV3細胞中不僅可抑制細胞的增生，並且可抑制p185HER2/neu 的蛋白質表現。本文發現大豆苷原可藉由在轉錄層面上抑制p185HER2/neu 的蛋白質表現；此外，本研究亦發現在高濃度的大豆苷原下加入SKOV3 細胞後能夠減弱由p185HER2/neu 調控的細胞位移以及轉移的可能性。因此本研究證實大豆苷原能夠抑制神經膠原致癌基因過度表現的人類卵巢癌SKOV3細胞的增生與移動性。

In the past study, daidzein, one isoflavone in Kudzu, could repress proliferation of colon, cervical, pancreatic and breast cancer cells. Human Epidermal Growth Factor 2 protein (HER2) , p185HER2/neu is over-expressed in sveral cancers. This study found that daidzein could not only inhibit cell proliferation of p185HER2/neu over-expressing ovarian carcinoma SKOV3 cells, but also repress p185HER2/neu protein expression. In the current study found daidzein suppresses the HER2 oncogene expression at the transcriptional level. In addition, this study also found that while treatment with daidzein at high concentration could reduce HER2-mediated transforming ability and metastatic potential of SKOV3 cells as compared with the vehicle control cells. Together, this study identified daidzein may against proliferation and migration of human HER2-overexpressing ovarian carcinoma SKOV3 cells in vitro.

謝誌 I
目錄圖目錄 III
圖目錄 V
附圖目錄 VI
附錄目錄 VII
附表目錄 VIII
縮寫表 IX
中文摘要 X
英文摘要 XI
第一章、緒論 (Introduction) - 1 -
第一節、神經膠原致癌基因(HER2) - 1 -
神經膠原致癌基因簡介 - 1 -
神經膠原致癌基因與癌症 - 1 -
針對神經膠原致癌基因的治療方法 - 3 -
神經膠原致癌基因與細胞轉移 - 4 -
第二節、大豆苷原 (Daidzein) - 6 -
大豆苷原簡介 - 6 -
大豆苷原與癌症 - 10 -
大豆苷原與神經膠原致癌基因 (HER2) - 10 -
第三節、研究動機與目的 - 12 -
第二章、材料與方法 (Materials and Methods) - 13 -
第一節、實驗材料與方法 - 13 -
一、大豆苷原配製方法 - 13 -
二、細胞培養 (Cell Culture) - 14 -
三、西方墨點法 (Western blotting) - 14 -
四、細胞生長速率分析 (MTT assay) - 15 -
五、錐藍排除分析 (Trypan blue dye exclusion assay) - 16 -
六、啟動子活性測定 (Luciferase assay and β-galactosidase assay) - 16 -
七、刮傷癒合分析（Scratch-Wound Healing Assay） - 18 -
八、統計分析 ( Statistical analysis ) - 19 -
第二節 主要儀器設備................................................................................................... - 20 -
第三章、 結果 (Results) - 23 -
第一節、大豆苷原造成卵巢癌細胞SKOV-3外觀形態的影響................................. - 23 -
第二節、大豆苷原抑制卵巢癌細胞SKOV-3存活率.................................................. - 23 -
第三節、大豆苷原抑制神經膠原致癌基因表現......................................................... - 24 -
第四節、大豆苷原抑制神經膠原致癌基因啟動子活性............................................. - 24 -
第五節、大豆苷原抑制卵巢癌細胞SKOV-3的移動性............................................. - 25 -
第四章、 討論 (Discussion) - 26 -
第五章、 結論 (Conclusion) - 27 -
第六章、參考資料 (Reference) - 28 -

Balabhadrapathruni S, Thomas TJ, Yurkow EJ, Amenta PS, Thomas T (2000) Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep 1:3-l2.
Beerli RR, Wels W, Hynes NE. (1994) Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem. 269(39):23931-6.
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie P, Yin S and Bast JRC (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091.
Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis, Oncogene 22 :6524–6536.
Bonfili L., Cecarini V., Amici M., Cuccioloni M., Angeletti M., Keller J.N., Eleuteri A.M. (2008) Natural polyphenols as proteasome modulators and their role as anti-cancer compounds. FEBS J. 275(22):5512-26.
Chiang CT, Way TD, Lin JK (2007) Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther. 6(7):2127-38
Choi, EJ (2006) The prooxidant, rather than antioxidant, acts of daidzein in vivo and in vitro: daidzein suppresses glutathione metabolism. Eur. J. Pharmacol. 542: 162–169.
Choi EJ, Kim GH (2008)Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine. 15(9):683-90.
Choi YH, Lee WH, Park KY, Zhang L (2000) p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91(2):164–l73.
Collins AR (2005) Antioxidant intervention as a route to cancer prevention. Eur. J. 41:1923–1930.
Crowder RJ, Lombardi DP, Ellis MJ (2004) Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell.6(2):103-4.
Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest. 96(6):2980-9.
Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in cancer. Sen,in Oncol. 31 (1 Suppl 3):9-20.
Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 23(11):2469-76.
Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: Antiepidermal growth factor receptor agents. J C in Onco. 25:4057-4065.
Jeong JH, An JY, Kwon YT, Li LY, Lee YJ (2008) Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem. 105(2):585-95.
Johnsen M, Lund LR, Rømer J, Almholt K, Danø K (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 10(5):667-71.
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. (2006)Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66(3):1630-9.
Li W, Weber G (l999) Synergistic action of tiazofurin and genistein on growth inhibition and differentiation of K562 human leukemic cells. Life Sci 22:l975–l98l.
Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 58(3):903-13.
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6(2):117-27.
Pathak SK, Sharma RA, Mellon JK (2003) Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (review). Int. J. Oncol. 22, 5–13.
Rao AV, Agarwal S. (2000) Role of antioxidant lycopene in cancer and heart disease. J. Am. Coll. Nutr. 19:563–569.
Sakla MS, Shenouda NS, Ansell PJ, Macdonald RS, Lubahn DB (2007) Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine. 32(1):69-78
Sarkar FH, Li Y (2003) Soy isoflavones and cancer prevention. Cancer Invest. 21(5):744-57.
Sato H, Takino T, Miyamori H (2005) Roles of membrane-typematrix metalloproteinase-1 in tumor invasion and metastasis, Cancer Sci. 96 :212–217.
Shao Z, Wu J, Shen Z. (2000)Genistein exerts multiple suppressive effects on human breast carcinoma cells. Zhonghua Zhong Liu Za Zhi. 22(5):362-5
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96(12):926-35.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177 -182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A andMcGuire WL (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science , 244(4905),707 - 712.
Sounni NE, Janssen M, Foidart JM, Noel A (2003) Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 22 :55–61.
Tan M, Yao J, Yu D (1997) Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57(6):1199-205.

Vihinen P, Kähäri VM. (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99 :157–166.
Way TD, Kao MC, Lin JK (2004) Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 279(6):4479-89
Way TD, Kao MC, Lin JK (2005) Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett. 579(1):145-52
Yu D and Hung M.C (1995). Molecular Basis of Oncology.Vol. 5. Freireich E and Stass SA (eds). Blackwell Scienti®cPublications Inc.: Cambridge, pp 131- 162.
Yu D, Hung MC. (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19(53):6115-21. Review.
Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK (l999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129 :l628–l635.
Zhang H, Berezov A, Wang Q ( 2007) ErbB receptors: From oncogenes to targeted cancer therapies. J C in Invest. 117:2051-2058.
羅瓊，郝近大，楊華，易紅 (2007) 葛根的本草考證. 中國中藥雜誌 第32卷第12期